

Z-11

Patented natural
technologies powering
next-generation hair-
loss solution

Pre-revenue
Pre-clinical complete
Human validation
initiating

Hair loss problem

- Hair loss is a massive, unsolved consumer problem
- Hundreds of millions affected globally
- Current choices force a trade-off:
 - Cosmetics → safe, limited efficacy
 - Drugs → effective, systemic side effects
- No daily solution bridges dermatology + consumer safety

The solution

- Z-11 built on patented biological signaling technologies
 - Topical, non-systemic
 - Designed for chronic, daily use
 - Targets hair follicle biology

Consumer-friendly today, clinically expandable tomorrow

PLATFORM OVERVIEW

- Two complementary technology pillars
 1. Follicular signaling modulation by specifically designed molecule
 2. Localized androgen receptor (AR) inhibition

Both delivered via topical **Z-11** formulations

TECHNOLOGY

1. Patented Technology (US20210115014A1)

- C-type & B-type molecules
- Designed to:
 - Reduce inflammatory signaling
 - Support hair-growth microenvironment
- Applicable across multiple alopecia types

2. Positioned as biological modulation

3. Why matter

- Broad applicability (AGA, stress-related, inflammatory alopecia)
- Favorable tolerability profile
- Differentiation vs minoxidil / finasteride
- Strong IP protection through 2041 (U.S.)

Feature	Z-11	Cosmetics	Oral Drugs
Biological targeting	✓	✗	✓
Topical & local	✓	✓	✗
Chronic use potential	✓	✓	✗
Patent protection	✓	✗	✓

IP moat

Strong and expanding global IP estate

- 1 core patent granted in: **United States, EU, Japan, and Australia.**
- Canada is currently pending.
- 3 granted Chinese patents
- **U.S. patent is valid until December 5, 2041**, providing long-term exclusivity in the U.S. market.

Validation status

- Completed pre-clinical studies
- Safety & mechanistic support established
- Outsourced GMP manufacturing in place
- Human validation study initiating
- Positioned as consumer dermatology validation

HUMAN VALIDATION STUDY

- 30 adult subjects
- 16–24 weeks
- Primary endpoints:
 - Hair density
 - Scalp condition markers
 - Tolerability & safety
- Build consumer credibility
- Support public-market valuation
- Prepare **NASDAQ transition**

MARKET OPPORTUNITY

- Global hair & scalp care market: multi-tens of billions
- Premium segment growing fastest
- Direct-to-consumer launch
- Selective retail partnerships
- Target gross margin: 60%+
- Long-term optional licensing (Asia/EU/America)

LEADERSHIP

- **Bongha Shin, Ph.D. — Founder & CEO**
 - Biochemist and serial entrepreneur; deep expertise in peptide-based therapeutics and consumer health commercialization
- **Yongheng Chen, MD, Ph.D. — Founder & CSO**
 - Physician-scientist specializing in dermatology and androgen biology; principal inventor on core patent estate
- **Advisory Board**
 - Independent clinical advisors in dermatology, regulatory strategy, and consumer DTC scaling — to be announced
- **Capital Structure**
 - No convertible debt | Founder control maintained | Clean cap table | GMP manufacturing outsourced

MARKET OPPORTUNITY

\$47B

Global TAM
Hair loss treatment

\$12B

SAM
Premium topical segment

\$600M

SOM (5-year)
DTC + licensing

- Global hair-loss treatment market ~\$47B; growing at 8% CAGR (Mordor Intelligence, 2024)
- Premium topical / derm-beauty crossover segment (\$12B SAM) is fastest-growing subsegment
- AGA alone affects ~85M Americans; global incidence: 50%+ of men and 40%+ of women by age 50
- Z-11 targets: DTC launch (US), selective retail, and long-term regional licensing (Asia / EU / Americas)

USE OF FUNDS — \$5M PRIVATE ROUND

\$2.0M (40%)

Human Validation Study

\$1.25M (25%)

GMP Manufacturing & Supply

\$750K (15%)

IP Prosecution & Legal

\$1.0M (20%)

G&A, Ops & Working Capital

- **This round funds three key de-risking milestones:**
 - Completion of 30-subject human validation study (16-24 weeks)
 - OTCQB listing via clean reverse merger (Super 8-K ready)
 - IP continuations filed in Canada, PCT expansion, and CN applications advancing

FINANCIAL PROJECTIONS (Pro Forma)

Metric	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5
• Revenue (\$M)	—	\$2.5M	\$8.0M	\$20M	\$42M
• Gross Margin	—	58%	62%	65%	67%
• EBITDA (\$M)	(\$5.0M)	(\$3.2M)	\$0.8M	\$6.5M	\$16M
• DTC Customers	—	8,000	25,000	65,000	130,000
• Key Milestone	Study+OTC	Launch	NASDAQ	Licensing	Intl Exp.

Key assumptions: \$299 avg. order value | 65% repeat rate | Licensing revenue begins Yr 4 | Illustrative estimates, not guarantees

3 weeks



control



minoxidil
solution



Z-11

Pre-clinical
study

clinical study

4 weeks

8 weeks



50 years old

Male

Spray once per day